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Cystic fibrosis ismostly caused by the F508del muta-
tion, which impairs CFTR protein from exiting the
endoplasmic reticulum due to misfolding. VX-809 is
a small molecule that rescues F508del-CFTR locali-
zation, which recently went into clinical trial but
with unknown mechanism of action (MoA). Herein,
we assessed if VX-809 is additive or synergistic
with genetic revertants of F508del-CFTR, other cor-
rectors, and low temperature to determine its MoA.
We explored and integrated those various agents in
combined treatments, showing how they add to
each other to identify their complementary MoA
upon correction of F508del-CFTR. Our experimental
and modeling data, while compatible with putative
binding of VX-809 to NBD1:ICL4 interface, also indi-
cate scope for further synergistic F508del-CFTR
correction by other compounds at distinct conforma-
tional sites/cellular checkpoints, thus suggesting
requirement of combined therapies to fully rescue
F508del-CFTR.
INTRODUCTION
Cystic fibrosis (CF), the most common autosomal recessive dis-
ease among Caucasians, is caused by mutations in the gene en-
coding the CF transmembrane conductance regulator (CFTR)
protein (Riordan et al., 1989). The most prevalent mutation
F508del occurs in more than 90% of CF patients (Riordan
et al., 1989), so most CF therapeutic efforts focus on the correc-
tion of this mutant.
CFTR possesses two transmembrane domains (TMD1/2), two
nucleotide binding domains (NBD1/2)—which bind and hydro-
lyse ATP, regulating the gating of the channel—and a regulatory
domain (RD), withmultiple phosphorylation sites (Riordan, 2008).
The F508del mutation causes CFTR to fail in reaching its
proper location at the plasma membrane (PM), instead being
mostly retained at the endoplasmic reticulum (ER) from where itChemistry & Biology 20,is rapidly sent to proteasomal degradation (Jensen et al., 1995).
Although failure in acquiring a native conformation is accepted
as the major cause for ER retention of F508del-CFTR, ultimately
it is the cellular machinery called the ER quality control (ERQC)
that actively disqualifies F508del-CFTR from exiting the ER
(Farinha and Amaral, 2005; Jensen et al., 1995). Our initial model
of the ERQC (Farinha and Amaral, 2005) proposed two check-
points involving the distinct Hsp70/Hsc70 and calnexin chap-
erone machineries, sequentially assessing the folding status of
CFTR and targeting for degradation nonnative protein conforma-
tion forms (reviewed in Amaral, 2004, 2011). Later, we postulated
a third ERQC checkpoint controlling CFTR ER export (Roxo-
Rosa et al., 2006), whereby misfolded F508del-CFTR fails to
exit the ER due to exposure of ER retention motifs—four argi-
nine-framed (RXR) tripeptides (AFTs)—whose substitution leads
to F508del-CFTR rescue (Chang et al., 1999; Roxo-Rosa et al.,
2006). In contrast, active ER export of WT-CFTR relies on the
presence of a diacidic code (NBD1-located ‘‘DAD’’ motif), a
cargo signal for Sec24-mediated COPII packing (Nishimura and
Balch, 1997).Wang et al. (2004) showed that alanine-substitution
of the second ‘‘DAD’’ Asp-residue in CFTR reduced both its
Sec24-CFTR association and ER exit. Additional evidence sup-
ports DAA-CFTR as a trafficking mutant without a major confor-
mational defect in contrast to F508del-CFTR, a conformational
mutant with a partially functional ER exit code (Roy et al., 2010).
Besides such cellular mechanisms (cell autonomous), F508del-
CFTR is also prevented from reaching the cell surface because of
its intrinsic abnormal folding (protein autonomous) caused by at
least three major defects. First, isolated CFTR F508del-NBD1
has an intrinsic folding defect, as shown by (1) impaired
F508del-NBD1 folding kinetics versus wild-type(WT)-NBD1 (Qu
and Thomas, 1996), (2) ability of some NBD1 amino acid variants
to both solubilize isolated F508del-NBD1 in vitro and also to
rescue in vivo full-length F508del-CFTR to the PM (Pissarra
et al., 2008), and (3) demonstrationbysurface-plasmon resonance
that F508del-NBD1 is a potent substrate of Hsp70 with 5-fold
higher affinity than theWTdomain (Scott-WardandAmaral, 2009).
The second F508del-associated defect impairs CFTR interdo-
main folding, namely, (1) the NBD1-NBD2 dimerization interface
(critical for channel activation and accounting for the F508del-
CFTR gating defect; Dalemans et al., 1991), which can be943–955, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 943
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Distinct Mechanisms Rescue F508del-CFTRrescued by the G550E revertant, and (2) the interaction of NBD1
with the fourth intracellular loop (ICL4) of TMD2 (Serohijos et al.,
2008), shown to be reverted by either V510D (Loo et al., 2010) or
R1070W, which both fill the pocket left empty by F508del (Thibo-
deau et al., 2010).
Third, when rescued F508del-CFTR reaches the cell surface, it
still presents a reduced half-life (Lukacs et al., 1993; Sharma
et al., 2001), due to both reduced recycling (Sharma et al.,
2004) and increased endocytosis (Swiatecka-Urban et al.,
2005). The latter was recently shown to be corrected by Rac1
signaling and HGF (Moniz et al., 2013).
Altogether, these protein-autonomous defects account for the
much reduced function of ER-rescued F508del-CFTR as a Cl
channel in comparison to its WT counterpart (Dalemans et al.,
1991). Efforts have thus been put into high-throughput
screening of small molecule libraries to identify correctors (Pe-
demonte et al., 2005) that rescue F508del-CFTR to the cell sur-
face, among which VX-809 is already in late-stage clinical trials
(Van Goor et al., 2011). Despite its impressive rescue levels in
primary cultures of CF patients’ lung cells, the success of this
compound in F508del-homozygous patients is modest (Clancy
et al., 2012), and its mechanism of action (MoA) has only very
recently begun to be understood (He et al., 2013; Okiyoneda
et al., 2013). Previous correctors (e.g., Corr-4a, VRT-325)
showed limited rescue of F508del-CFTR, probably due to action
exerted at one of the multiple mutant defects (Grove et al., 2009;
Varga et al., 2008).
Herein, we explored the MoA of VX-809 by analyzing its syn-
ergistic/additive effect with those of previously characterized
genetic revertants, which rescue F508del-CFTR by causing
different effects: 4RK affecting traffic (Roxo-Rosa et al.,
2006), G550E (Roxo-Rosa et al., 2006) and R555K increasing
channel gating by strengthening the NBD1:NBD2 dimer inter-
face, and R1070W (Serohijos et al., 2008) and V510D (Wang
et al., 2007a; Loo et al., 2010) by filling the NBD1:ICL4 inter-
face. Finally, we also tested VX-809 together with low tem-
perature (Denning et al., 1992) and the Corr-4a, VRT-325
correctors.
Our data show that VX-809 and the two other correctors exert
variable effects on the genetic revertants and support VX-809
putative binding at the interface of NBD1 with TMD2 ICL4
consistently with our modeling data and recent findings from
others published while this paper was under review (He et al.,
2013; Okiyoneda et al., 2013). Interestingly, VX-809 adds up to
the two other correctors in the rescue of F508del-CFTR and
also with low temperature. Altogether, these data lead us to
conclude that there is scope for correction beyond VX-809 at
distinct F508del-CFTR conformational sites/cellular folding
checkpoints. Moreover, combined therapeutic strategies to
rescue F508del-CFTR may be required to reach the threshold
of functional CFTR necessary to avoid CF.
RESULTS
VX-809 Fails to Promote Folding of Isolated F508del-
NBD1
To assess the thermal stability of murine CFTRNBD1 (either WT-
or F508del) in the presence of chemical correctors, we used dif-
ferential scanning fluorimetry (DSF), which monitors the thermal944 Chemistry & Biology 20, 943–955, July 25, 2013 ª2013 Elsevier Lunfolding of the protein in the presence of fluorescent Sypro Or-
ange dye (Niesen et al., 2007). As the dye is highly sensitive to
nonpolar environments (exposed during unfolding), fluorescence
also increases with protein unfolding. By plotting fluorescence
intensity as a function of temperature, a sigmoidal curve
describing a two-state transition (Figure S1 available online) is
generated, and the inflection point of the transition curve corre-
sponds to the melting temperature (Tm). The traces correspond-
ing to the control experiments already point to a higher destabi-
lization of murine F508del- versus WT-NBD1, due to both lower
Tm and also higher initial dye intensity, indicative of a less
compact fold. The assays with VX-809, VRT-325, and Corr-4a
correctors (using a protein:compound 1:1 stoichiomety) did not
reveal any potential of NBD1 stabilization (Table S1). Notwith-
standing, a preliminary study with VX-809 suggests that it may
exert an effect on the reorganization of the NBD1 fold, as it de-
creases Sypro binding intensity at 37C (C.M.G., unpublished
data). Although this effect does not increase the domain thermo-
dynamic stability, it effectively modulates its unfolding kinetics.
VX-809 Adds to VRT-325 and Corr-4a to Rescue
F508del-CFTR but Exhibits Variable Effects on Genetic
Revertants
In order to characterize the rescue mechanism of VX-809 on
F508del-CFTR, we then tested the effect of incubating it together
with VRT-325 and Corr-4a on BHK cells stably expressing this
mutant alone or in cis with the following genetic revertants: (1)
4RK (where the four AFTs were simultaneously mutated to ly-
sines), (2) G550E, (3) R1070W, (4) V510D, or (5) R555K (Figures
1A–1E). Processing of eachCFTR variant was assessed bywest-
ern blot (WB; Figures 1A–1E) andmeasured as the percentage of
fully processed (band C) to total CFTR (band C + immature form
band B) and then normalized to the same WT-CFTR ratio
(Figure 1F).
Incubation with each of the compounds VX-809, Corr-4a, or
VRT-325 led to the appearance of fully processed F508del-
CFTR, as previously (Loo et al., 2005; Pedemonte et al., 2005;
Van Goor et al., 2011) albeit with different efficacy: 24%, 9%,
and 19%, respectively. Furthermore, data analysis shows that
VX-809 rescue of F508del-CFTR adds to that by Corr-4a or
VRT-325 and also to that of the two latter compounds together
(Figures 1A and 1G), suggesting that these three small molecules
act by distinct MoA. Some rescue of F508del-CFTR by DMSO
acting as a chemical chaperone was also detected as previously
noted by many others (see, e.g., Pedemonte et al., 2005; Varga
et al., 2008).
Interestingly, however, analysis of the effects of the three com-
pounds upon the revertants showed that VX-809 (but neither
VRT-325 nor Corr-4a) is additive to G550E or R555K in correct-
ing F508del-CFTR (by 38% and 32%, respectively), strongly
suggesting that VX-809 acts differently from these two rever-
tants. Moreover, whereas both VRT-325 and VX-809 add signif-
icantly to the effect of R1070W by 17% (p = 0.011) and 28%
(p = 1.6 105), respectively, Corr-4a does not. In contrast, all
the three compounds produce a significant increase in the
amount of processed F508del-4RK-CFTR (Figure 1G), suggest-
ing that 4RK acts differently. Curiously, all the three compounds
further increase band C levels of F508del-V510D-CFTR, but
VRT-325 produces the greatest effect.td All rights reserved
Figure 1. Effect of Small Molecule Correctors on F508del-CFTR and Genetic Revertants
(A–F) BHK cell lines stably expressing CFTR bearing F508del alone (A) or in cis with 4RK (B), G550E (C), R1070W (D), V510D (E), and R555K (F) were incubated for
24 hr with 6.7 mMVRT-325, 10 mMCorr-4a, or 3 mMVX-809 alone or in combination. CFTR protein was analyzed bywestern blot with the anti-CFTR 596mAb. Data
are representative of n = 7 independent experiments.
(G) For each condition, densitometry was used to calculate the percentage of band C to total CFTR expressed. Data were normalized toWT-CFTR and are shown
as mean ± SEM. Asterisks indicate significant difference from the same CFTR variant with DMSO (p < 0.05). Dotted lines correspond to levels of band C in
revertants without treatment.
See also Figure S1 and Table S1.
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Distinct Mechanisms Rescue F508del-CFTRPotency of Correctors in Increasing Processing of
Revertants
To further understand the effect of the small molecule com-
pounds on the genetic revertants, we analyzed the dose
response of processing by the correctors (Figures 2A–2C). These
analyses were performed for three of the revertants with different
F508del-CFTR effects (4RK, traffic; G550E, NBD1:NBD2 dimer
interface; and R1070W, NBD1:ICL4 interface).
Results show that, in general, much lower corrector concen-
trations are needed to increase revertants processing in compar-
ison to those required to rescue F508del-CFTR. For example, an
increase in F508del-G550E-CFTR processing is detected at
0.3 mM VX-809, whereas a 10-fold higher concentration is
needed for significant rescue of F508del-CFTR (Figure 2C).
Additive Effects of Small Molecule Correctors and Low
Temperature
To shed more light on the MoA of F508del-CFTR rescue by VX-
809, we next tested its effects (and the effects of VRT-325 andChemistry & Biology 20,Corr-4a) under low temperature by incubating cells for 48 hr at
26C alone or in the presence of each corrector (or DMSO con-
trol) for the last 24 hr (Figures 2D and 2E).
Additive/synergistic effects on F508del-CFTR rescue were
detected between each corrector and low temperature. Rescue
of F508del-CFTR by VX-809 at 26C reached z80% of WT-
CFTR processing, i.e., an additional (statistically significant)
z40% increase compared to low temperature alone, whereas
VRT-325 and Corr-4a at 26C reachedz60% of WT-CFTR (Fig-
ure 2E). These data suggest that low temperature acts on
F508del-CFTR differently from the three correctors.
CFTR Modeling
To better understand our experimental findings, we modeled
CFTR (Figure 3) based on the published NBD1 X-ray data
(Lewis et al., 2010). The full protein was modeled based on
the structure of Sav1866 (Hohl et al., 2012). Where such data
were not available, we resorted to constructing homology
models.943–955, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 945
Figure 2. Potency of Correctors on Genetic Revertants and with Low Temperature
(A–C) BHK cell lines stably expressing CFTR bearing F508del alone or in cis with the indicated genetic revertants were incubated for 24 hr with (A) 6.7, 67, and
670 nM and 1, 6.7, or 20 mM VRT-325, (B) 1, 10, and 100 nM and 1, 10, or 25 mM Corr4a, or (C) 3, 30, and 300 nM and 3, 10, or 30 mM VX-809. CFTR protein was
analyzed by western blot with the anti-CFTR 596 mAb. Data are representative of n = 4 independent experiments. For each condition, densitometry was used to
calculate the percentage of band C to total CFTR expressed. Data were normalized to WT-CFTR and are shown as mean ± SEM.
(D) BHK cell lines stably expressing CFTR bearing F508del were incubated for 48 hr at 26C along with VRT-325, Corr-4a, or VX-809 for the final 24 hr. CFTR
protein was analyzed by WB.
(E) Percentage of band C versus total CFTR. Asterisks indicate significant difference from the F508del-CFTR at 26C under treatment with DMSO - control (p <
0.05). Dotted line corresponds to levels of band C in F508del-CFTR at 26C.
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Distinct Mechanisms Rescue F508del-CFTROur full-lengthmodel (Figure 3A) depictsWT-CFTRwithout the
RD and with ATP bound to the two sites (shown in space-filling
mode) at the NBD1:NBD2 interface. It recapitulates critical inter-
domain interactions already predicted by others (Serohijos et al.,
2008), identifying the proximity of the F508-containing NBD1
surface with ICL4 of TMD2 (Figure S2A).
To understand the structural differences between WT- and
F508del-NBD1, we overlaid published structures (2BBT and
2BBO, respectively) (Lewis et al., 2010) by sequence and sec-
ondary structure (Figure 3B). As previously shown, the most
evident difference is the absence of the aromatic ring of
F508 at the surface of the mutant domain. Further, the overlay
of the two domains allows the identification of a significant differ-
ence in the 573–580 loop (as highlighted in the lower inlay, Fig-
ure 3B), adjacent to Asp572 (Walker B). Still in this loop,
Tyr577 interacts with ATP in WT-NBD1 but rearranges to a distal
position in F508del-NBD1, contributing to a certain loosening of
the mutant structure (Figure 3C).
Modeling of the NBD1:NBD2 heterodimer ATP site was
based on the NBD1 homodimer structure (Protein Data Bank
[PDB] ID code: 2PZE) (Atwell et al., 2010), in which one half
was used as a template for overlay of NBD2 (PDB ID code:
3GD7). Further refinement of the overlay on the ATP sites
yielded an authentic heterodimer model. These models allowed
the search for differential contact sites (Figures 3D and 3E), and
their analysis showed the presence of two contact sites in946 Chemistry & Biology 20, 943–955, July 25, 2013 ª2013 Elsevier LWT-CFTR that are severely altered in F508del-CFTR: one cor-
responding to the previously described interaction of ICL4
and NBD1 (Serohijos et al., 2008) (also shown in Figure S2A)
and the second to the interface of the two NBDs around the
ATP sites.
We then assessed the effect of revertants G550E and R1070W
by modeling (Figure 3F; Figures S2B and S2C), whereby G550E
allows a salt bridge to form across the ATP binding site with
Lys1250 and other residues from NBD2 (Figure 3F). By contrast,
R1070W (Figure S2A) plausibly fills in the space left empty by
absence of F508 at the NBD1:ICL4 interface as previously pro-
posed (Thibodeau et al., 2010).
Investigation of the F508del-CFTR model using ligand binding
site finding algorithm ‘‘Q-SiteFinder’’ led us to the strong likeli-
hood that CFTR correctors or potentiators bind to one of two
sites, namely, at the NBD1:NBD2 or the NBD1:ICL4 interfaces.
Then, using docking and scoring techniques, to determine which
of these two binding sites best accommodate correctors, we
propose that, whereas VRT-325 is best accommodated by the
ATP site at the NBD1:NBD2 interface (Figure 3G), VX-809 is a
good fit for the pocket left empty by F508 at the NBD1:ICL4
interface (Figure 3H). We did not find a good fit for Corr-4a in
either of these proposed sites. Although these putative binding
sites resulted from our highest scoring results, we should
acknowledge that there is some uncertainty associated with
this modeling approach.td All rights reserved
Figure 3. Modeling of CFTR Structure to Identify Critical Interactions as well as Similarities and Differences betweenWT- and F508del-NBD1
(A) Full model of WT-CFTR without R-domain and with ATP at both sites based on Sav1866.
(B) Overlay of WT- and F508del-NBD1 with the major differences highlighted.
(C) Interaction of loop 573-580 with ATP in WT-NBD1.
(D) The NBD1:NBD2 dimer interface sites that bind ATP and AMP.
(E) The site between ICL4 and NBD1 proximal to the F508del mutation.
(F) Change in F508del NBD1-NBD2 heterodimer interface by the second-site mutation G550E.
(G) Docking of corrector VRT-325 to the ATP site. VRT-325 is shown with gray carbons docked in the ATP site of NBD1-NBD2 heterodimer (transparent dot
surface), overlaid on the ATP analog from 3 dg7.pdb (shown with green carbons).
(H) Docking of corrector VX-809 to the F508del-CFTR pocket created at the NBD1:ICL4 interface.
See also Figure S2.
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Distinct Mechanisms Rescue F508del-CFTRRescue of F508del-CFTR by Low Temperature Is
Additive to Genetic Revertants
To learn more about how low temperature rescues F508del-
CFTR, we assessed its combined effect with that of the
above genetic revertants: G550E, R1070W, 4RK, V510D,
and R555K (Figures 4A and 4B). Results show that low temper-
ature further increases processing levels of F508del-CFTR by
the five genetic revertants, namely, V510D, G550E, R1070W,
4RK, and R555K, by an additional 35%, 65%, 38%, 27%,Chemistry & Biology 20,and 22%, respectively (compare gray and black bars in
Figure 4B).
As a negative control, we also analyzed the effect of low tem-
perature on CFTR bearing another class II disease-causing mu-
tation R560T (Roxo-Rosa et al., 2006), confirming its previously
described insensitivity to low temperature rescue (Figures 4A
and 4B).
These data with revertants again suggest that low temperature
configures a different mechanism of rescue, as was the case943–955, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 947
Figure 4. Second-Site Mutations Are Additive to Each Other and Low Temperature in the Rescue of F508del-CFTR
(A) BHK cell lines stably expressing CFTRWT or bearing the mutations indicated were cultured at 37C or incubated at 26C for 48 hr as indicated. CFTR protein
was analyzed by WB. Data are representative of n = 5–9 experiments.
(B) For each variant, densitometry was used to calculate the percentage of band C versus total CFTR. This percentage was normalized toWT-CFTR and is shown
as mean ± SEM. Asterisks indicate significant difference from the same CFTR variant at 37C (p < 0.05).
(C) BHK cell lines stably expressing CFTRWTor different variants were cultured at 37Cor incubated at 26C for 48 hr as indicated. CFTRprotein was analyzed by
WB. Data are representative of n = 5–9 experiments.
(D) For each variant, densitometry was used to calculate the percentage of bandC versus total CFTR, as in (B). Asterisks indicate significant difference from single
genetic revertants. + indicates significant difference from the same variant at 37C (p < 0.05). The dotted line corresponds to levels of band C in F508del-G550E-
CFTR.
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Distinct Mechanisms Rescue F508del-CFTRwith the correctors. Interestingly, these additive effects were
observed not only for revertants promoting protein-autonomous
folding (G550E, V510D, and R1070W) but also for the 4RK rever-
tant, which bypasses the AFT-mediated ER retention.
Combination of Different Genetic Revertants Is Also
Additive
Next, to assess the full potential for F508del-CFTR rescue, we
combined the effects of folding and traffic revertants by produc-
ing stable BHK cell lines expressing F508del-G550E-CFTR,
where 4RK, V510D, or R1070W were also added in cis, and
analyzed processing (Figures 4C and 4D). Results in Figure 4C
show that 4RK, V510D, and R1070W further increased process-
ing of G550E-F508del-CFTR by another 12%, 59%, and 70%,
respectively. In fact, the combined effects of G550E with either
V510D or R1070W bring F508del-CFTR processing to z80%,
i.e., close to levels of WT-CFTR, which can be further increased
at 26C reaching 88%. The combination of G550E with 4RK,
although additive, has a more modest effect (32% in total) and
is still additive to low temperature (Figure 4D, far right bar).
Low Temperature Kinetics of F508del-CFTR Alone or
with 4RK/G550E
The increased effect of combining correctors, revertants, and
low temperature is strongly suggestive of different MoAs. How-
ever, to further characterize the MoA of low temperature rescue,948 Chemistry & Biology 20, 943–955, July 25, 2013 ª2013 Elsevier Lwe studied the turnover rate and processing efficiency of
F508del-CFTR or in cis with 4RK/G550E at 26C in comparison
to these variants at 37C. Pulse-chase experiments followed
by CFTR-immunoprecipitation (IP) were thus performed in cells
incubated at 26C and then chased at either 26C or 37C (Fig-
ure 5A). In parallel, control experiments fully at 37C were also
performed.
Data show that the turnover rate ofWT-CFTR band Bwas sub-
stantially decreased when cells were incubated at 26C and then
chased at 37C (Figure 5A, middle five lanes) in comparison to
cells always at 37C (Figure 5A, first five lanes), and this differ-
ence was even more striking when the chase was also at 26C
(Figure 5A, last five lanes). Because this significant decrease in
turnover rate of band B (Figure 5B) did not correspond to an in-
crease in its processing, i.e., conversion into the fully-glycosy-
lated band C (Figure 5C), we can conclude that it corresponds
to decreased degradation.
The same experiments for F508del-CFTR (Figures 5D and 5E)
show that, similarly to WT-CFTR, the turnover rate of immature
F508del-CFTR is significantly reduced in cells incubated and
chased at 26C (Figure 5D, last five lanes and Figure 5E), with
only the processed form (band C) being barely detectable. How-
ever, when the chase was performed at 37C (Figure 5D, middle
five lanes), the turnover rate of band B was similar to that in cells
always at 37C, with no band B being detected, which suggests
its rapid degradation once at 37C.td All rights reserved
Figure 5. F508del-CFTR Accumulates in Its
ER-Specific Immature Form in Cells Incu-
bated at Low Temperature
(A–D) Pulse-chase experiments followed by
immunoprecipitation were performed in BHK ex-
pressing (A)WT- or (D) F508del-CFTR incubated at
26C for 48 hr. After labeling at 26C for 3 hr, chase
was performed at either 37C (middle five lanes) or
26C (last five lanes). Cells incubated at 37C and
labeled for 30 min at 37C were also analyzed as a
control (first five lanes). Turnover rate of immature
form (band B) of (B) WT- or (E) F508del-CFTR was
measured as the logarithm of ratio of labeled
protein at time t (P) to the amount of labeled protein
at the start of the chase (P0). Conversion of the
immature form (band B) into the mature form of
WT-CFTR (band C) (C) was measured as the per-
centage of band C at time t relative to the amount
of labeled protein at the start of chase. Symbols
and error bars are means ± SEM of n = 3 values at
each time point. One asterisk indicates the line
whose slope is significantly different from that of
control line—cells incubated at 37C (p < 0.05).
See also Figure S3.
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Distinct Mechanisms Rescue F508del-CFTRWe then similarly assessed how low temperature affects the
turnover and processing of F508del-CFTR bearing the two
genetic revertants 4RK and G550E (Figure 6). Results from
pulse-chase experiments of F508del-G550E-CFTR show a
dramatic reduction in the turnover of the immature form (Fig-
ure 6A, left panel), which also corresponds to an increase in its
processing efficiency (band C levels) when the chase was per-
formed at 26C (Figure 6A). Data from similar experiments at
26C with the 4RK revertant on F508del-CFTR (Figure 6A, right
panel) also show that low temperature decreased band B turn-
over rate, when the chase was performed at 26C, but only
modestly. Interestingly, this effect did not result in an increase
in the processing efficiency (Figure 6A, right panel).
The differential behavior observed for F508del-G550E- and
F508del-4RK-CFTR at 26C becomes most evident when these
data are plotted as the total amount of band B + band C against
time (Figures 6B and 6C). Indeed, whereas the total amount of
F508del-G550E-CFTR at 26C (Figure 6B, gray/dotted bars)
onlybarelydecreases incomparison to its total at37C(Figure6B,Chemistry & Biology 20, 943–955, July 25, 2013black/striped bars), the total amount of
F508del-4RK-CFTR displays a marked
time course decrease either at 26C (Fig-
ure 6B, gray/dotted bars) or at 37C (Fig-
ure 6C, black/striped bars). The observed
results are consistent with CFTR func-
tional data for these variants, as assessed
by the iodide (I) efflux technique (Fig-
ure S4). Altogether they indicate that
4RK is not as additive to low temperature
in stabilizing F508del-CFTR as G550E.
Correction of CFTR Bearing
Mutants of the Diacidic ER Code
To further dissect the rescue mech-
anisms of F508del-CFTR rescue byVX-809, namely, in relation to ER-to-Golgi traffic, we also
tested its rescue effect (as well as that of the other two cor-
rectors, low temperature, and genetic revertants) on a CFTR
mutant with a defective ER-export DAD-code (Wang et al.,
2004).
We first mutated the second residue (Asp567) in the ER DAD-
exit codeDAA (Figure 7A). As shown previously (Roy et al., 2010),
this mutation does not fully abolish CFTR processing, resulting in
a z55% decrease of processing versus WT-CFTR (Figure 7A).
We then tested the effect of either correctors or low temperature
on this mutant to find that both VX-809 and low temperature in-
crease processed CFTR levels (Figure 7B). Further, AFTs
removal from DAA-CFTR (4RK-DAA-CFTR) also increases
band C levels (Figure 7B).
Because we aimed to achieve the complete impairment of
traffic of WT-CFTR (Wang et al., 2004), we thus generated an
additional mutant through abrogation of both Asp565 and
Asp567 residues in the DAD-motif of the ER-exit code (DD/AA-
CFTR mutant).ª2013 Elsevier Ltd All rights reserved 949
Figure 6. Low Temperature Stabilizes the Immature Form of G550E and 4RK Variants of F508del-CFTR and Acts Synergistically with G550E,
but not 4RK, to Rescue F508del-CFTR
(A–C) Pulse-chase experiments followed by IP were performed in BHK cells expressing (A) F508del-G550E (left panel) or F508del-4RK-CFTR (right
panel) incubated at 26C for 48 hr. After labeling with [35S] methionine for 3 hr, chase was performed at 26C (last five lanes in each panel). The same cells were
labeled for 30 min and chased always at 37C as control (first five lanes). Percentage of bands B and C present at each time point of chase in F508del-G550E- (B)
or F508del4RK-CFTR (C) incubated for the duration of the experiment (pulse + chase) at either 26C or 37C is shown in graph bars to illustrate the additive effect
of low temperature and the genetic revertant G550E, but not 4RK, on F508del-CFTR rescue. Symbols and error bars aremeans ± SEMof n = 5 values at each time
point.
See also Figure S4.
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Corr-4a) or at 26C (Figures 7C and 7D). Results show that
neither VX-809 nor VRT-325 and Corr-4a could rescue DD/AA-
CFTR maturation, and interestingly the abrogation of the AFT
motifs in this export mutant (DD/AA-4RK-CFTR) was also inef-
fective. But remarkably, low temperature did rescue the defect
caused by elimination of the diacidic code (Figure 7C).
Again, these data were confirmed by the iodide-efflux tech-
nique showing that low temperature did indeed rescue ion chan-
nel function of DD/AA-CFTR (triangles, Figure 7E) to z50% of
WT-CFTR (circles, Figure 7E), whereas DD/AA-CFTR cells did
not elicit detectable I-efflux (squares, Figure 7E), consistently
with its traffic defect and similarly to F508del-CFTR (Figure 7F).
A summary of magnitude of peak I-efflux generated by DD/
AA-CFTR (Figure 7E) and F508del-CFTR (Figure 7F) expressed
as a percentage ofWT-CFTR (Figure 7G) shows that low temper-
ature rescues these two variants byz50% andz40%, respec-
tively, and the difference between these values was found to be
statistically significant.
DISCUSSION
The goal of the major corrective therapies for CF, like the inves-
tigational drug VX-809, is to rescue the most frequent disease-950 Chemistry & Biology 20, 943–955, July 25, 2013 ª2013 Elsevier Lcausing mutant, F508del-CFTR, to the plasma membrane. Pre-
vious studies have shown that this can be achieved by different
rescue strategies, namely, (1) by correcting the folding of the
mutant protein (either by enhancing NBD1 folding or by promot-
ing interdomain packing) or (2) by releasing the mutant protein
from its ER retention through overcoming the barriers imposed
by several checkpoints of the ER quality control (Farinha and
Amaral, 2005; Rosser et al., 2008; Roxo-Rosa et al., 2006).
Other groups have tested combined treatments to rescue pro-
cessing of F508del-CFTR (He et al., 2010; Thibodeau et al.,
2010). Here, focusing mostly on genetic revertants, but also
low temperature and other correctors, we have looked into the
investigational drug VX-809 by also comparing and integrating
the effects by those various agents in further combinations.
VX-809 Adds to Genetic Revertants and Other
Correctors to Rescue F508del-CFTR
Our data show that rescue of F508del-CFTR by VX-809 is addi-
tive to that achieved by either genetic revertants or the other cor-
rectors (VRT-325 and Corr-4a). These findings strongly suggest
distinct MoA for those three compounds but also demonstrate
that full correction of F508del-CFTR can be maximized to reach
the processing levels of WT-CFTR by using a combination of
strategies.td All rights reserved
Figure 7. CFTR with Mutated Diacidic Exit Code Is Rescued by Low Temperature, but Not by Correctors
(A) BHK cell lines stably expressing WT-CFTR or bearing the DAA (D567A) mutation alone or in ciswith 4RK were cultured at 37C, incubated at 26C for 48 hr or
for 24hr with VRT-325, Corr-4a, or VX-809, as indicated. CFTR protein was analyzed by WB. Data are representative of n = 5 experiments.
(B) For each variant, densitometry was used to calculate the percentage of band C versus total CFTR. This percentage was normalized toWT-CFTR and is shown
as mean ± SEM.
(C) BHK cell lines stably expressingWT-CFTR or bearing the DD/AA mutations (D565A, D567A) alone or in ciswith 4RK were cultured at 37C, incubated at 26C
for 48 hr or for 24 hr with VRT-325, Corr-4a, or VX-809, as indicated. CFTR protein was analyzed by WB. Data are representative of n = 6 experiments.
(D–F) For each variant, densitometry was used to calculate the percentage of band C versus total CFTR, as in (B). Functional analysis of CFTR variants was
assessed by iodide efflux from BHK cells stably expressing (E) WT-, DD/AA- at 37C and 26C and (F) WT-, F508del-CFTR at 37C and 26C.
(G) Magnitude of peak iodide efflux generated by the different CFTR constructs is determined for each condition as a percentage ofWT-CFTR. Symbols and error
bars are means ± SEM of n = 6 values at each time point. Asterisks indicate significant difference from respective controls at 37C (p < 0.05).
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Distinct Mechanisms Rescue F508del-CFTRImportantly, when we analyzed whether VX-809 is additive
with revertants known to rescue F508del-CFTR by different
mechanisms, we found quite significant differences (Figure 1),
which provide clues to the MoA of this compound. Indeed, VX-
809 (in contrast to either VRT-325 or Corr-4a) adds to the rescue
by G550E and R555K (both acting at the NBD1:NBD2 interface),
indicating that the compound and these two revertants probably
correct distinct conformational cues of F508del-CFTR. In
contrast, the additive effect of VX-809 to R1070W and V510D
is rather modest, thus suggesting that this corrector acts more
similarly to R1070W/V510D than to G550E/R555K.
VRT-325 in turn (and comparatively to its modest effect alone)
significantly increases (by z29% versus VRT-325 alone) theChemistry & Biology 20,rescue efficiency of R1070W and also V510D, suggesting effects
at distinct sites.
Potency of correctors (Figures 2A–2C) on revertants
showed that compounds act at lower doses than for F508del-
CFTR. For example, F508del-G550E-CFTR required a 10-fold
lower dose of VX-809 than F508del-CFTR for significant rescue.
As proposed before (Thibodeau et al., 2010), F508del-CFTR
rescue needs a coordinated effect of both NBD1 correction
and interdomain assembly. So, the increased potency of the
correctors upon revertants versus F508del-CFTR suggests
that an already partially corrected version of the protein (by
the revertants in cis) is much more easily diverted to a fully cor-
rected conformation—once again, pointing out to the need for943–955, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 951
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Distinct Mechanisms Rescue F508del-CFTRa combined multistep action to more effectively rescue this
mutant.
Structural Implications: Putative Correction of the
NBD1:ICL4 Interface by VX-809
These observations are further strengthened by our modeling
studies, which highlighted two putative contact sites in WT-
CFTR that are severely altered in F508del-CFTR and are plau-
sible binding sites for CFTR modulators: one at the NBD1:NBD2
interface and another at the NBD1:ICL4 interface, as previously
described (Serohijos et al., 2008). Furthermore, docking and
scoring techniques suggest that VX-809 is a good fit for the
ICL4 site, whereas VRT-325 is best accommodated by the
ATP site (Figures 3G and 3H), and Corr-4a does not fit at either
of these sites. This is also consistent with the DSF data showing
that none of the three compounds promoted isolated NBD1
folding (Figure S1). Therefore, these compounds should stabilize
interdomain interactions: the NBD1:ICL4 interface (VX-809) or
the NBD1:NBD2 dimer interface (VRT-325).
However, there is some degree of uncertainty associated with
the docking studies and using the final CFTR-folded form may
preclude effects by correctors acting on a folding intermediate.
Nevertheless, while this paper was under review, others reported
similar findings using modeling to elucidate the MoA for VX-809,
although allosteric effects could not be excluded as modes of
action (He et al., 2013). Importantly, those published data also
indicate that VX-809 does not restore the thermodynamic stabil-
ity of F508del-CFTR, as one would expect for a compound sta-
bilizing a folding intermediate. So, altogether, results from this
recent study by He et al. (2013) further support our proposal
that VX-809 docks to the NBD1:ICL4 interface. Our findings
are also in agreement with recent work from Okiyoneda et al.
(2013), who show that VX-809 primarily corrects the destabiliza-
tion of the NBD1:ICL4 interface caused by absence of F508.
Corr-4a seems to act by an unspecific mechanism as
this compound is also able to rescue trafficking mutants of
MC4R, melanocortin receptor 4 (J.B.C. Findlay, personal
communication), suggesting an unspecific role as a chemical
chaperone. In support of this hypothesis, Corr-4a diminished
the binding affinity of F508del-NBD1 to the chaperone Hsc70
(Scott-Ward and Amaral, 2009). Also, consistently, Corr-4a
acts by a distinct MoA from VRT-325 and VX-809, as there is sig-
nificant (although modest) synergy between Corr-4a and the
other two compounds.
Furthermore, modeling also predicts that revertants G550E
and R1070W act at different CFTR interdomain contacts disrup-
ted by F508del: whereas G550E seems to restore the strength of
the NBD1:NBD2 interface, R1070W rather promotes the
NBD1:ICL4 interaction, as suggested previously (He et al.,
2010; Serohijos et al., 2008) and in Figure S2A. Data on combi-
nation of the different revertants are fully consistent with this pre-
diction. Indeed, G550E, besides being able to promote rescue of
F508del-CFTR (DeCarvalho et al., 2002), shows the largest com-
bined effect with R1070W (or V510D). These data plausibly indi-
cate that correction at both sites is required for full rescue of
F508del-CFTR.
Moreover, the observed synergy of G550E or R555K with
VX-809, but not VRT-325, is consistent with this model in which
VRT-325 acts on the NBD1:NBD2 dimerization interface (also952 Chemistry & Biology 20, 943–955, July 25, 2013 ª2013 Elsevier Lsupported by the synergy between R1070W and VRT-325).
Further modeling is, however, required to examine the observa-
tion that R1070W is still additive with VX-809 (albeit modestly).
This putative effect of VRT-325 is in agreement with its previously
reported rescue effect upon P-glycoprotein (Wang et al., 2007c),
which also belongs to the ABC transporter superfamily, but not
upon mutations in SCN1A, the voltage-gated sodium channel
Na(V)1.1, a quite unrelatedmembrane protein responsible for se-
vere myoclonic epilepsy of infancy (Thompson et al., 2012).
VX-809 and Low Temperature Rescue F508del-CFTR
Processing toz80% of WT-CFTR
Low temperature showed very strong additive effects with
VX-809 reaching z80% of WT-CFTR processing levels. VRT-
325 and Corr-4a also added to low temperature but to a lower
extent (z60% of WT-CFTR). These data suggest that low tem-
perature acts on F508del-CFTR differently from the three correc-
tors, and this led us to further investigate its MoA.
We found that at 26C WT-CFTR significantly accumulates in
its immature form, probably due to impairment of pre-Golgi
structures to translocate efficiently at this temperature (Lippin-
cott-Schwartz et al., 2000), leading to an accumulation of cargo
proteins at the ER exit sites (Presley et al., 1998). F508del-CFTR
also accumulates, but once cells are at 37C, while the ER-accu-
mulated WT-CFTR rapidly traffics to the plasma membrane,
most F508del-CFTR is degraded, with only a minor fraction
reaching the cell surface (Figure 5). To explain accumulation of
the immature form, our results from biosynthesis, trafficking,
and degradation of F508del-CFTR at 26C (Figure S3) confirmed
that translation still proceeds, albeit more slowly, whereas pro-
teasomal degradation is reduced as also described (Velickovska
et al., 2005). Thus, reduced temperature appears to provide
F508del-CFTR a kinetic folding advantage as shown for
F508del-NBD1 in vitro (Qu and Thomas, 1996), allowing its accu-
mulation instead of proteasomal degradation. However, such
conformation is only intrinsically stable as long as the tempera-
ture is low, as suggested by others (Lukacs and Verkman, 2012).
The low maturation levels detected for F508del-CFTR at 26C
incubation (Figure 5D) are probably also derived from its
described membrane instability (Lukacs et al., 1993; Sharma
et al., 2001). In fact, we recently showed that increasing Rac1
signaling by HGF significantly stabilizes CFTR at the plasma
membrane and that treatment with HGF alone rescues
F508del-CFTR activity to 10% of WT-CFTR (Moniz et al.,
2013). Moreover, HGF adds to VX-809, achieving 30% rescue
of the mutant, consistent with the reported inability of VX-809
to restore F508del-CFTR thermodynamic stability (He et al.,
2010).
Our data also show that low temperature, similar to chemical
correctors, further increases processing levels of F508del-
CFTR by the five genetic revertants, although to variable levels:
V510D (by an additional 35%), G550E (65%), R1070W (38%),
4RK (27%), and R555K (22%).
The strong synergistic effect of low temperature andG550E on
the rescue of F508del-CFTR-efficient processing, but only
modestly for 4RK, supported by pulse-chase data, suggest
that low temperature and 4RK effects are mechanistically closer
to each other (and thus related to bypassing the ER quality con-
trol) than low temperature and G550E. This is further supportedtd All rights reserved
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Distinct Mechanisms Rescue F508del-CFTRby the additive effects of G550E and 4RK effects (Figure 4). Inter-
estingly, others have found that F508del-CFTR associates
poorly with Sec24, but this may be reversed by low temperature
incubation (Wang et al., 2004), thus providing a further explana-
tion in relation to traffic for the mechanism of this long-known
F508del-CFTR rescue strategy (Denning et al., 1992). Although
4RK can also be claimed to impact on F508del-CFTR folding
(namely, through its two NBD1 changes: R516K and especially
R555K), this is somewhat disproven by the additive effects of
4RK with G550E (Figure 4), the latter truly correcting F508del-
NBD1 folding, as assessed by channel gating (Farinha and Ama-
ral, 2005; Rosser et al., 2008; Roxo-Rosa et al., 2006).
VX-809 Enhances DAA Traffic, but Does Not Rescue the
Traffic-Deficient Mutant DD/AA
Finally, we tested how VX-809 (as well as VRT-325 and Corr-4a)
affected the traffic of diacidic exit code mutants of CFTR.
Whereas DAA did not completely abolish processing of CFTR,
as previously reported (Roy et al., 2010), VX-809, 4RK, and low
temperature further increased its processing levels. Evidence
from others suggested DAA-CFTR to be a trafficking mutant
withoutamajor conformationaldefect (Royet al., 2010).However,
the double diacidic mutant DD/AA-CFTR, is the one we found to
completely impair appearance of band C. Moreover, this variant
was not corrected by any of the compounds tested, suggesting
that this trafficking mutant cannot be corrected by pharmaco-
logical chaperones. Curiously, the abrogation of the AFT motifs
in this export mutant was also ineffective, suggesting the
independence of defective ER export and dominant AFT-medi-
ated ER retention mechanisms. As the F508del-CFTR rescue by
VX-809 is additive to that of 4RK, it is plausible that this compound
does not affect AFT-mediated dominant ER retention.
Very interestingly, however, low temperature could rescue
DD/AA-CFTR. This again suggests that low temperature allows
this variant to exit the ER, and this should occur through conven-
tional ER-to-Golgi traffic. Indeed, it is highly unlikely that low
temperature promotes DD/AA-CFTR ER exit through the
recently proposed nonconventional GRASP55-mediated traf-
ficking pathway (Gee et al., 2011), as we show that the temper-
ature-rescued DD/AA-CFTR is fully glycosylated, in contrast to
cargo undergoing nonconventional traffic.
Altogether, these data show that VX-809, in contrast to low
temperature, cannot overcome the Sec24-COPII-export defect
of DD/AA-CFTR.
SIGNIFICANCE
This study highlights the existence of multiple correction
mechanisms accounting for the rescue of F508del-CFTR,
themost common CF-causing mutant. Assessing the syner-
gistic/additive effects of investigational drug VX-809, one of
the most promising to rescue the F508del-CFTR-trafficking
defect, with those of genetic revertants as well as other cor-
rectors (VRT-325 and Corr-4a) or low temperature pointed to
major insights into its MoA: (1) VX-809 is additive to both
VRT-325 andCorr-4a, suggesting that each compound oper-
ates by a different MoA; (2) VX-809 is additive to low temper-
ature rescue of the mutant almost to WT-CFTR levels; (3)
VX-809, VRT-325, and Corr-4a show variable additive effectsChemistry & Biology 20,with the genetic revertants tested (4RK, G550E, and
R1070W), thus providing clues for their possible action being
exerted at specific protein binding pockets: VX-809 at the
NBD1:TMD2 interface (andVRT-325atNBD1:NBD2) or acting
unspecifically (Corr-4a); and (4) VX-809 does not rescue the
diacidic code traffic mutant in contrast to low temperature,
which seems to act at trafficking surveillance checkpoints.
Besides suggesting a MoA for VX-809, our data also
indicate the scope for further synergistic F508del-CFTR
correction by other compounds at distinct conformational
sites/cellular checkpoints. Accordingly, they provide a plau-
sible explanation for the limited success of VX-809 in clinical
trials, proposing that this compound alone may be insuffi-
cient to ascertain clinically relevant CFTR levels at the cell
surface. Therefore, combination therapies may be required
to achieve complementary rescue by distinct MoA’s and
full F508del-CFTR correction, so as to reach the functional
CFTR threshold necessary to avoid CF. The ‘‘best’’ strategy
to bring F508del-CFTR rescue to WT-CFTR functional levels
should thus probably involve the combination of several
small molecules, each acting on a different step in the com-
plex pathway of F508del-CFTR folding, trafficking, plasma
membrane stability, and function. These findings should be
exploited for therapeutic strategies of CF.
EXPERIMENTAL PROCEDURES
Cells and Culture Conditions
BHK cell lines expressing F508del-4RK (R29K/R516K/R555K/R716K)-,
F508del-G550E-, F508del-R1070W-, F508del-V510D-, F508del-R555K-,
F508del-V510D/G550E-, F508del-G550E/R1070W-, DAA (D567A)-, 4RK-
DAA-, DD/AA (D565A, D567A)-, 4RK-DD/AA-, and R560T-CFTR were pro-
duced and cultured as previously described (Roxo-Rosa et al., 2006). For
low temperature experiments, cells were incubated at 26C for the indicated
periods of time. The small molecule correctors VRT-325 (Wang et al., 2007b)
used at 6.7 mM and Corr-4a (Pedemonte et al., 2005) used at 10 mM were ob-
tained through Cystic Fibrosis Foundation Therapeuticals. VX-809 was ob-
tained from Selleck Chemicals and used at 3 mM for 24 hr (Van Goor et al.,
2011). For potency tests, cells were incubated for 24 hr with VRT-325:
6.7 nM, 67 nM, 670 nM, 1.0 mM, 6.7 mM, or 20 mM; Corr4a: 1.0 nM, 10 nM,
100 nM, 1.0 mM, 10 mM, or 25 mM; or VX-809: 3.0 nM, 30 nM, 300 nM,
3.0 mM, 10 mM, or 30 mM. As vehicle control, cells were also incubated with
DMSO alone at the same concentration used when in presence of correctors,
i.e., 0.1% (v/v), and this was used as the baseline control.
CFTR Homology Model
Our model was based on the alignment of human CFTR sequence (MSDs and
NBDs) with the Staphylococcus aureus Sav1866 sequence, to preserve the
interface features between the different domains and on the published struc-
ture of this bacterial ABC transporter (Hohl et al., 2012).
NBD1/NBD2 heterodimer was constructed by overlay using sequence and
secondary structure of NBD2 from 3DF7 with the heterodimer structure of
F508del 2PZE (Atwell et al., 2010).
Modeling was performed as a whole using MOE software from the Chemical
Computing Group (Molecular Operating Environment [MOE], 2011.10; Chem-
ical Computing Group). For investigation of putative binding sites for com-
pounds on themonomeric NBD1 and the dimeric NBD1/NBD2, we used ligand
binding site finding algorithm Q-SiteFinder (Laurie and Jackson, 2005).
Western Blot
To probe for the effect of low temperature, genetics revertants, and com-
pounds upon CFTR processing by western blot (WB), cells were incubated
with each compound at a chosen concentration for 24 hr at either 37C or
26C, as indicated. After incubation, cells were lysed and extracts analyzed943–955, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 953
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Distinct Mechanisms Rescue F508del-CFTRas described previously (Farinha et al., 2002) using the anti-CFTR antibody 596
(CFF). Percentage of band C to total CFTR was calculated by normalizing the
ratio of band C/ total CFTR (bands B+C) relatively to the same ratio in samples
from WT-CFTR expressing cells as a control.
Pulse-Chase and Immunoprecipitation
After incubation at 26C, cells expressing CFTR were starved for 30 min in
methionine-free medium and then pulsed for 30 min at 37C or for 3 hr at
26C in the same medium supplemented with 150 mCi [35S]methionine.
Pulse-chase experiments, followed by immunoprecipitation of CFTRwere per-
formed as previously described (Farinha et al., 2002).
Iodide Efflux
CFTR-mediated iodide efflux was measured at room temperature using the
cAMP agonist forskolin (10 mM) and the CFTR potentiator genistein (50 mM;
Sigma-Aldrich) as described previously (Lansdell et al., 1998; Roxo-Rosa
et al., 2006).
Statistical Analysis
Quantitative results are shown asmeans ± SEMof n observations. To compare
two sets of data, we used Student’s t test when differences are significant for p
values < 0.05.
Differential Scanning Fluorimetry
The effect of small compounds on the thermal stability of murine WT- and
F508del-NBD1 was evaluated through DSF (Lavinder et al., 2009; Senisterra
and Finerty, 2009). Briefly, the different compound solutions were distributed
into PCR plates (Bio-Rad), and protein solution with Sypro Orange 5-fold
(Invitrogen) was added to each well. Plates were sealed with optical quality
sealing tape (Bio-Rad) and run in an iCycler iQ Real-Time thermocycler instru-
ment (Bio-Rad) using an excitation filter from 530 to 560 nm and an emission
filter from 575 to 595 nm. Temperature was increased from 20C to 90C, with
increments of 2C.min1. The fits of the unfolding transitions were carried out
using Origin (MicroCal) assuming a two-state model. For each condition, the
midpoint transitions (melting temperatures, Tm) were determined (Pace
et al., 1998). Protein concentration was 4 mM in the case of the wild-type
NBD1 and 6 mM for NBD1-F508del. Experiments were performed in 20 mM
sodium phosphate (pH 7.4) and 1 mM DTT.
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